Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study

R. Buzzoni; S. Pusceddu; P. Biondani; M. Cantore; E. Aitini; A. Bertolini; ALABISO Oscar; L. Isa; G. Pinotti; E. Bajetta

doi:10.1016/S0959-8049(11)71937-2

Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study

R. Buzzoni, S. Pusceddu, P. Biondani, M. Cantore, E. Aitini, A. Bertolini, ALABISO Oscar, L. Isa, G. Pinotti, E. Bajetta

Risultato della ricerca: Contributo alla conferenza › Poster

Lingua originale	Inglese
Pagine	S479-S480
Numero di pagine	2
DOI	https://doi.org/10.1016/S0959-8049(11)71937-2
Stato di pubblicazione	Pubblicato - 1 gen 2011
Pubblicato esternamente	Sì
Evento	European Multidisciplinary Cancer Congress - Stockholm, Sweden Durata: 1 gen 2011 → …

???event.eventtypes.event.conference???

???event.eventtypes.event.conference???	European Multidisciplinary Cancer Congress
Città	Stockholm, Sweden
Periodo	1/01/11 → …

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/S0959-8049(11)71937-2

Altri file e collegamenti

handle

Cita questo

Buzzoni, R., Pusceddu, S., Biondani, P., Cantore, M., Aitini, E., Bertolini, A., Oscar, ALABISO., Isa, L., Pinotti, G., & Bajetta, E. (2011). Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study. S479-S480. Sessione di poster presentata al European Multidisciplinary Cancer Congress, Stockholm, Sweden. https://doi.org/10.1016/S0959-8049(11)71937-2

@conference{b5c2b17604d34f3ea7e15a3e474d412d,

title = "Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study",

author = "R. Buzzoni and S. Pusceddu and P. Biondani and M. Cantore and E. Aitini and A. Bertolini and ALABISO Oscar and L. Isa and G. Pinotti and E. Bajetta",

year = "2011",

month = jan,

day = "1",

doi = "10.1016/S0959-8049(11)71937-2",

language = "English",

pages = "S479--S480",

note = "European Multidisciplinary Cancer Congress ; Conference date: 01-01-2011",

}

Buzzoni, R, Pusceddu, S, Biondani, P, Cantore, M, Aitini, E, Bertolini, A, Oscar, ALABISO, Isa, L, Pinotti, G & Bajetta, E 2011, 'Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study', European Multidisciplinary Cancer Congress, Stockholm, Sweden, 1/01/11 pagg. S479-S480. https://doi.org/10.1016/S0959-8049(11)71937-2

Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study. / Buzzoni, R.; Pusceddu, S.; Biondani, P. et al.
2011. S479-S480 Sessione di poster presentata al European Multidisciplinary Cancer Congress, Stockholm, Sweden.

Risultato della ricerca: Contributo alla conferenza › Poster

TY - CONF

T1 - Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study

AU - Buzzoni, R.

AU - Pusceddu, S.

AU - Biondani, P.

AU - Cantore, M.

AU - Aitini, E.

AU - Bertolini, A.

AU - Oscar, ALABISO

AU - Isa, L.

AU - Pinotti, G.

AU - Bajetta, E.

PY - 2011/1/1

Y1 - 2011/1/1

UR - https://iris.uniupo.it/handle/11579/58371

U2 - 10.1016/S0959-8049(11)71937-2

DO - 10.1016/S0959-8049(11)71937-2

M3 - Poster

SP - S479-S480

T2 - European Multidisciplinary Cancer Congress

Y2 - 1 January 2011

ER -

Buzzoni R, Pusceddu S, Biondani P, Cantore M, Aitini E, Bertolini A et al.. Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study. 2011. Sessione di poster presentata al European Multidisciplinary Cancer Congress, Stockholm, Sweden. doi: 10.1016/S0959-8049(11)71937-2